Generic Medicine Info
Should be taken on an empty stomach. Take 15-30 min before meals.
Prolactin-releasing pituitary tumour (prolactinoma), existing QTc interval prolongation, significant electrolyte disturbances (e.g. hypokalaemia, hypomagnesaemia, hyperkalaemia), underlying cardiac disease (e.g. CHF), gastrointestinal haemorrhage, mechanical obstruction or perforation. Moderate to severe hepatic impairment. Concomitant use with QT-prolonging drugs, and potent CYP3A4 inhibitors e.g. ketoconazole, macrolide (e.g. erythromycin), protease inhibitors, or nefazodone.
Special Precautions
Patients with personal or family history of breast cancer, risk factors for sudden cardiac death (e.g. family history of coronary artery disease, high blood pressure, high blood cholesterol, diabetes mellitus, obesity, smoking, excessive alcohol consumption). Renal and mild hepatic impairment. Children and elderly. Pregnancy and lactation. Patient counselling This drug may cause dizziness and somnolence, if affected, do not drive or operate machinery. Monitoring Parameters Monitor ECG, renal function at baseline and periodically during treatment.
Adverse Reactions
Significant: Elevated prolactin levels, hypersensitivity reactions (e.g. anaphylaxis, angioedema). Rarely, neurological or extrapyramidal side effects (in children). Eye disorders: Oculogyric crisis. Gastrointestinal disorders: Dry mouth, diarrhoea, transient intestinal cramps. General disorders and administration site conditions: Asthenia. Immune system disorders: Urticaria. Investigations: Abnormal LFT. Nervous system disorders: Headache, migraine, dizziness, convulsions. Psychiatric disorders: Anxiety, agitation, nervousness, loss of libido, somnolence. Renal and urinary disorders: Urinary retention. Reproductive system and breast disorders: Galactorrhoea, breast pain or tenderness, gynaecomastia, amenorrhoea. Skin and subcutaneous tissue disorders: Rash, pruritus.
Potentially Fatal: Serious ventricular arrhythmias, sudden cardiac death, QT interval prolongation, torsades de pointes.
Drug Interactions
May increase risk of QT interval prolongation with azithromycin, roxithromycin, and with bradycardia- and hypokalaemia-inducing drugs. May decrease bioavailability with antacids or antisecretory agents. May antagonise the prokinetic effects of anticholinergics (e.g. bromocriptine). Increased plasma concentrations of levodopa.
CIMS Class
Antiemetics / GIT Regulators, Antiflatulents & Anti-Inflammatories
ATC Classification
A03FA03 - domperidone ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.
Disclaimer: This information is independently developed by CIMS based on domperidone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in